Laura Muñoz1, Aina Gomila2, Susana Casas3, José Castellote4, Montserrat Arnan5, Antoni Rafecas6, Miguel Santin1. 1. Departments of Infectious Diseases, Bellvitge University Hospital-IDIBELL, Barcelona, Spain.; Department of Clinical Sciences, University of Barcelona, Barcelona, Spain. 2. Departments of Infectious Diseases, Bellvitge University Hospital-IDIBELL, Barcelona, Spain. 3. Department of Internal Medicine, Consorci Sanitari Integral-Dos de Maig Hospital, Barcelona, Spain. 4. Department of Gastroenterology and Liver Transplant Unit, Bellvitge University Hospital-IDIBELL, Barcelona, Spain. 5. Department of Hematology, Duran i Reynals Hospital, Barcelona, Spain. 6. Department of General Surgery and Liver Transplant Unit, Bellvitge University Hospital-IDIBELL, Barcelona, Spain.
Abstract
BACKGROUND: Little is known about the predictive value for progression to tuberculosis (TB) of interferon-γ release assays and how they compare with the tuberculin skin test (TST) in assessing the risk of TB infection in transplant recipients. METHODS: We screened 50 liver transplant (LT) and 26 hematopoietic stem cell transplant (HSCT) recipients with both QuantiFERON-TB Gold In-tube (QFT-GT) and TST and prospectively followed them for a median of 47 months without preventive chemoprophylaxis. RESULTS: In the LT cohort, 1 in 22 (4.5%) QFT-GT-positive patients developed posttransplant TB, compared with none of the QFT-GT-negative patients. In the HSCT cohort, none of the 7 QFT-GT-positive patients developed TB, whereas 1 case (5.3%) progressed to active TB among the 19 QFT-GT-negative patients. Comparable results were obtained with the TST: in the LT group, 1 of 23 TST-positive and none of the 27 TST-negative patients developed TB; and in the HSCT group, none of the 8 TST-positive and one of the 18 TST-negative patients progressed to active TB. CONCLUSIONS: In this cohort of transplant recipients, the positive predictive value of QFT-GT for progression to active TB was low and comparable to that of TST. Although the risk of developing TB in patients with negative results at baseline is very low, some cases may still occur.
BACKGROUND: Little is known about the predictive value for progression to tuberculosis (TB) of interferon-γ release assays and how they compare with the tuberculin skin test (TST) in assessing the risk of TB infection in transplant recipients. METHODS: We screened 50 liver transplant (LT) and 26 hematopoietic stem cell transplant (HSCT) recipients with both QuantiFERON-TB Gold In-tube (QFT-GT) and TST and prospectively followed them for a median of 47 months without preventive chemoprophylaxis. RESULTS: In the LT cohort, 1 in 22 (4.5%) QFT-GT-positive patients developed posttransplant TB, compared with none of the QFT-GT-negative patients. In the HSCT cohort, none of the 7 QFT-GT-positive patients developed TB, whereas 1 case (5.3%) progressed to active TB among the 19 QFT-GT-negative patients. Comparable results were obtained with the TST: in the LT group, 1 of 23 TST-positive and none of the 27 TST-negative patients developed TB; and in the HSCT group, none of the 8 TST-positive and one of the 18 TST-negative patients progressed to active TB. CONCLUSIONS: In this cohort of transplant recipients, the positive predictive value of QFT-GT for progression to active TB was low and comparable to that of TST. Although the risk of developing TB in patients with negative results at baseline is very low, some cases may still occur.
Authors: Susana Casas; Laura Muñoz; Raquel Moure; Jose Castellote; Maria R Guerra; Lucia Gonzalez; Ana Andreu; Antoni G Rafecas; Fernando Alcaide; Miguel Santin Journal: Liver Transpl Date: 2011-10 Impact factor: 5.799
Authors: N Theodoropoulos; F Lanternier; J Rassiwala; G McNatt; L Preczewski; E DeMayo; V Stosor; M G Ison Journal: Transpl Infect Dis Date: 2011-08-26 Impact factor: 2.228
Authors: S-H Kim; S-O Lee; J B Park; I-A Park; S J Park; S-C Yun; J H Jung; Y H Kim; S C Kim; S-H Choi; J-Y Jeong; Y S Kim; J H Woo; S-K Park; J S Park; D J Han Journal: Am J Transplant Date: 2011-07-12 Impact factor: 8.086
Authors: Julián Torre-Cisneros; Antonio Doblas; José María Aguado; Rafael San Juan; Marino Blanes; Miguel Montejo; Carlos Cervera; Oscar Len; Jordi Carratala; José Miguel Cisneros; Germán Bou; Patricia Muñoz; Antonio Ramos; Merce Gurgui; Nuria Borrell; Jesus Fortún; Asunción Moreno; Joan Gavalda Journal: Clin Infect Dis Date: 2009-06-15 Impact factor: 9.079
Authors: Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka Journal: Nat Med Date: 2020-10-19 Impact factor: 53.440